MAPT and Alzheimer disease: Conclusion: Our data suggested that T-006 mitigated cognitive decline by reducing Aβ deposition through reducing APP production, reducing p-tau and total tau through autophagy-related JNK and mTOR-ULK1 signaling pathways, supporting further investigation into its development as a candidate drug for AD treatment.